Latest Blog Posts Tagged "Academia/Nonprofit"
March 19, 2018
Acquisitions can bring experience and funds to move Parkinson's therapies through testing and to patient hands faster.
March 08, 2018
With a new drug on the market to treat PD symptoms, it's important to discuss why you might consider one drug over another.
September 20, 2017
How does dyskinesia impact people with PD? An MJFF-funded measurement scale captured those perceptions and helped a new drug get approved to treat it.
September 14, 2017
In this video, Dr. Dolhun talks about a common side effect of levodopa and how it can be managed.
August 24, 2017
Adamas Pharmaceuticals announced FDA approval of extended-release amantadine for levodopa-induced dyskinesia in PD.
April 26, 2017
This week, Adamas Pharmaceuticals announced new data for a dyskinesia drug -- an extended-release formulation of amantadine designed to be taken once daily at bedtime.
February 10, 2017
MJFF funded early research of this novel drug candidate, mGluR4, helping remove financial and other barriers to advance its testing.
January 10, 2017
The FDA recently agreed to review the New Drug Application for a dyskinesia medication developed by Adamas Pharmaceuticals.
October 31, 2016
A new drug for levodopa-induced dyskinesia is one step closer to potentially reaching market.
September 21, 2016
A new formulation of amantadine to better treat levodopa-induced dyskinesia is entering the home stretch.